Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
Authors:
Open Access
- 24 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (46) , 81285-81294
Abstract
Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.Keywords
This publication has 20 references indexed in Scilit:
- CYP3A5 Polymorphism Effect on Cyclosporine Pharmacokinetics in Living Donor Renal Transplant Recipients: Analysis by Population PharmacokineticsAnnals of Pharmacotherapy, 2012
- [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].2012
- Optimization of Initial Tacrolimus Dose Using Pharmacogenetic TestingClinical Pharmacology & Therapeutics, 2010
- Urinary fractalkine is a marker of acute rejectionKidney International, 2008
- A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 GenotypeTransplantation, 2008
- Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose ImmunosuppressantsTransplantation, 2004
- The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoringClinical Transplantation, 2002
- The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groupsClinical Pharmacology & Therapeutics, 2001
- RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1Transplantation, 1998
- Racial variation in dosage requirements of tacrolimusThe Lancet, 1996